Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Capricor Therapeutics (CAPR) Operating Expenses (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Operating Expenses data on record, last reported at $26.3 million in Q3 2025.

  • For Q3 2025, Operating Expenses rose 72.11% year-over-year to $26.3 million; the TTM value through Sep 2025 reached $97.8 million, up 64.74%, while the annual FY2024 figure was $64.8 million, 31.63% up from the prior year.
  • Operating Expenses reached $26.3 million in Q3 2025 per CAPR's latest filing, down from $27.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $27.7 million in Q2 2025 and bottomed at $4.3 million in Q3 2021.
  • Average Operating Expenses over 5 years is $13.0 million, with a median of $11.7 million recorded in 2023.
  • The widest YoY moves for Operating Expenses: up 126.84% in 2021, down 9.76% in 2021.
  • A 5-year view of Operating Expenses shows it stood at $6.4 million in 2021, then skyrocketed by 41.49% to $9.0 million in 2022, then surged by 48.12% to $13.4 million in 2023, then surged by 40.83% to $18.8 million in 2024, then skyrocketed by 39.6% to $26.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $26.3 million in Q3 2025, $27.7 million in Q2 2025, and $25.0 million in Q1 2025.